00:00Today this drug arrives in Italy with a very specific indication in patients with lymphoma
00:13mantle that have already received two therapeutic lines, one with a covalent type Btk inhibitor
00:24and from a point of view of therapeutic needs, it is a drug aimed at a very challenging disease
00:33in which, however, it has given some really, really egregious answers.
00:40And then it is a drug that stands out for an innovative mechanism, therefore, compared to the other inhibitors
00:48always of the Btk, which are, let's say, irreversible inhibitors, therefore, with a mechanism of action
00:57very, in quotation marks, vigorous, Pirtobrutinib is a reversible inhibitor, therefore, with a mechanism of action
01:05much more dynamic, much more flexible and which, however, continues to associate with a persistent inhibition
01:15of the molecular target and this is important because the therapeutic response descends from the inhibition.
01:22Let's imagine we have in front of us the patient, he is a patient who is usually quite ahead of his age,
01:29therefore, very often he presents himself to treatments with some cardiovascular and metabolic morbidity,
01:36he is a patient with a challenging proliferative lymphoma disease, he is a patient who has already had other therapeutic lines,
01:45therefore, Pirtobrutinib, as it is framed in this scenario, it is framed as a drug that is effective,
01:52because we reflect on the fact that it intervenes when the patient has detached himself from the previous lines,
02:02an effective drug, a tolerable drug, also because many times passing from one drug to another
02:08depends on the tolerability, as well as on the presence or less of the therapeutic action.
02:14Therefore, it is a drug that, if we can use this terminology, has all the characteristics to agree with the patient
02:23and a good drug-patient relationship, even if it is not a scientific dimension, becomes a therapeutic dimension.
Comments